Generic placeholder image

Current Cancer Drug Targets

Author(s): Amal A. Mohamed, Aymen S. Yassin, Basma S. Gomaa, Hossam Darwish, Rasha S. Mohamed, Sahar Makled, Ahmed Ramdan, Sherief Abd-Elsalam* and Marwa M. Raafat

DOI: 10.2174/1568009621666210302090917

DownloadDownload PDF Flyer Cite As
Association of Polymorphism in Survivin Gene and the Risk of Liver Cancer Resulting from Hepatitis C Virus Among Egyptian Patients

Page: [536 - 543] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: This study aims to investigate the relation between Survivin gene polymorphisms and the risk of Hepatocellular carcinoma (HCC) resulting from hepatitis C infection among the Egyptian population.

Methods: This prospective study was conducted on 164 patients, 57 patients were diagnosed with hepatitis C, where 57 were diagnosed with HCC in addition to 50 healthy volunteers as controls. Genotyping for Survivin rs1042489 and rs8073069 single nucleotide polymorphisms was carried out by the allelic discrimination Real-Time Polymerase Chain Reaction Single Nucleotide Polymorphisms genotyping technology.

Results: The results of Survivin rs1042489 polymorphism revealed that the TC and CC genotypes were significantly different between hepatocellular carcinoma patients (OR=15.5, 95%CI: 3.299-72.825,P<0.001), and controls (OR=44, 95%CI: 8.025-241.254, P<0.001). Furthermore, CC genotype was significantly different between cirrhotic and hepatocellular carcinoma patients (OR=19.2, 95%CI: 3.097-119.049, P=0.002). Moreover, the TC genotype shows a significant difference between controls and cirrhotic patients (OR=5.5, 95%CI: 2.111-14.328, P<0.001). However, when comparing TT genotypes, CC+TC genotypes results showed a significant association with increasing the risk of cirrhosis and hepatocellular carcinoma (OR=4.812, 95%CI: 1.893-12.233, P=0.001), (OR=21.607, 95%CI: 4.738-98.532, P<0.01), respectively. On the other hand, there was no significant difference among all studied groups for all genotypes regarding Survivin rs8073069. Also, the CC+GC genotype showed no significant association with increased risk of hepatocellular carcinoma (P=0.999) compared with the GG genotypes.

Conclusion: The study indicates that functional Survivin rs1042489 polymorphism may contribute to the risk of hepatocellular carcinoma while Survivin rs8073069 polymorphism has no significant association with increased risk of hepatocellular carcinoma among the studied groups.

Keywords: HCC, HCV, SNP, Survivin, gene, Egypt, BIRC5, apoptosis, RT-PCR.

[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
[http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID: 15761078]
[2]
El-Serag, H.B.; Rudolph, K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132(7), 2557-2576.
[http://dx.doi.org/10.1053/j.gastro.2007.04.061] [PMID: 17570226]
[3]
Dragani, T.A. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol., 2010, 52(2), 252-257.
[http://dx.doi.org/10.1016/j.jhep.2009.11.015] [PMID: 20022654]
[4]
Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 2006, 6(9), 674-687.
[http://dx.doi.org/10.1038/nrc1934] [PMID: 16929323]
[5]
Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer, 2005, 5(11), 845-856.
[http://dx.doi.org/10.1038/nrc1739] [PMID: 16239904]
[6]
Shepelev, M.V.; Kopantzev, E.P.; Vinogradova, T.V.; Sverdlov, E.D.; Korobko, I.V. hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study. Oncol. Lett., 2016, 12(2), 1204-1210.
[http://dx.doi.org/10.3892/ol.2016.4718] [PMID: 27446419]
[7]
Yamamoto, T.; Tanigawa, N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron Microsc., 2001, 34(4), 207-212.
[http://dx.doi.org/10.1007/s007950100017] [PMID: 11956993]
[8]
Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 1998, 58(23), 5315-5320.
[PMID: 9850056]
[9]
Asanuma, K.; Moriai, R.; Yajima, T.; Yagihashi, A.; Yamada, M.; Kobayashi, D.; Watanabe, N. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res., 2000, 91(11), 1204-1209.
[http://dx.doi.org/10.1111/j.1349-7006.2000.tb00906.x] [PMID: 11092988]
[10]
Yazdani, N.; Sayahpour, F.A.; Haghpanah, V.; Amiri, P.; Shahrabi-Farahani, M.; Moradi, M.; Mirmiran, A.; Khorsandi, M.T.; Larijani, B.; Mostaan, L.V.; Amoli, M.M. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol. Res. Pract., 2012, 208(2), 100-103.
[http://dx.doi.org/10.1016/j.prp.2011.12.009] [PMID: 22293278]
[11]
Borbély, A.A.; Murvai, M.; Szarka, K.; Kónya, J.; Gergely, L.; Hernádi, Z.; Veress, G. Survivin promoter polymorphism and cervical carcinogenesis. J. Clin. Pathol., 2007, 60(3), 303-306.
[http://dx.doi.org/10.1136/jcp.2006.037804] [PMID: 16714396]
[12]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[13]
El-Gebaly, F.; Abou-Saif, S.; Elkadeem, M.; Helmy, A.; Abd-Elsalam, S.; Yousef, M.; Elkhouly, R.A.; Amer, I.F.; El-Demerdash, T. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in egyptian patients. Curr. Cancer Drug Targets, 2019, 19(11), 896-905.
[http://dx.doi.org/10.2174/1568009619666190718141647] [PMID: 31538897]
[14]
Kawata, N.; Tsuchiya, N.; Horikawa, Y.; Inoue, T.; Tsuruta, H.; Maita, S.; Satoh, S.; Mitobe, Y.; Narita, S.; Habuchi, T. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int. J. Cancer, 2011, 129(8), 1872-1880.
[http://dx.doi.org/10.1002/ijc.25850] [PMID: 21154810]
[15]
Hsieh, Y.S.; Tsai, C.M.; Yeh, C.B.; Yang, S.F.; Hsieh, Y.H.; Weng, C.J. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann. Surg. Oncol., 2012, 19(3)(Suppl. 3), S625-S633.
[http://dx.doi.org/10.1245/s10434-011-2123-3] [PMID: 22052111]
[16]
Jaiswal, P.K.; Goel, A.; Mandhani, A.; Mittal, R.D. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol. Biol. Rep., 2012, 39(5), 5615-5621.
[http://dx.doi.org/10.1007/s11033-011-1366-1] [PMID: 22193624]
[17]
Schur, B.C.; Bjerke, J.; Nuwayhid, N.; Wong, S.H. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin. Chim. Acta, 2001, 308(1-2), 25-31.
[http://dx.doi.org/10.1016/S0009-8981(01)00422-3] [PMID: 11412814]
[18]
Weng, C.J.; Hsieh, Y.H.; Chen, M.K.; Tsai, C.M.; Lin, C.W.; Yang, S.F. Survivin SNP-carcinogen interactions in oral cancer. J. Dent. Res., 2012, 91(4), 358-363.
[http://dx.doi.org/10.1177/0022034512438402] [PMID: 22318371]
[19]
Chan, Y. Biostatistics 102: quantitative data–parametric & non-parametric tests. blood pressure., 2003.
[20]
Chan, Y.H. Biostatistics 103: qualitative data - tests of independence. Singapore Med. J., 2003, 44(10), 498-503.
[PMID: 15024452]
[21]
Chan, Y.H. Biostatistics 104: correlational analysis. Singapore Med. J., 2003, 44(12), 614-619.
[PMID: 14770254]
[22]
Cohen, C.; Lohmann, C.M.; Cotsonis, G.; Lawson, D.; Santoianni, R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol., 2003, 16(6), 574-583.
[http://dx.doi.org/10.1097/01.MP.0000073868.31297.B0] [PMID: 12808063]
[23]
Gazouli, M.; Tzanakis, N.; Rallis, G.; Theodoropoulos, G.; Papaconstantinou, I.; Kostakis, A.; Anagnou, N.P.; Nikiteas, N. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int. J. Colorectal Dis., 2009, 24(2), 145-150.
[http://dx.doi.org/10.1007/s00384-008-0601-2] [PMID: 18946675]
[24]
Chen, J.; Cui, X.; Zhou, H.; Qin, C.; Cao, Q.; Ju, X.; Li, P.; Cai, H.; Zhu, J.; Meng, X.; Wang, M.; Zhang, Z.; Shao, P.; Li, J.; Yin, C. Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer, 2013, 13(1), 356.
[http://dx.doi.org/10.1186/1471-2407-13-356] [PMID: 23883402]
[25]
Javid, J.; Mir, R.; Julka, P.K.; Ray, P.C.; Saxena, A. Role of survivin re-expression in the development and progression of non-small cell lung cancer. Tumour Biol., 2015, 36(7), 5543-5550.
[http://dx.doi.org/10.1007/s13277-015-3224-6] [PMID: 25677909]
[26]
Xu, Y.; Fang, F.; Ludewig, G.; Jones, G.; Jones, D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol., 2004, 23(9), 527-537.
[http://dx.doi.org/10.1089/dna.2004.23.527] [PMID: 15383173]
[27]
Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 1997, 3(8), 917-921.
[http://dx.doi.org/10.1038/nm0897-917] [PMID: 9256286]
[28]
Knizhnik, A.V.; Kovaleva, O.V.; Laktionov, K.K.; Mochalnikova, V.V.; Komelkov, A.V.; Tchevkina, E.M. Zborovskaya and I.B. “Arf6, RalA, and BIRC5 protein expression in nonsmall cell lung cancer. Mol. Biol., 2011, 45(2), 275-282.
[http://dx.doi.org/10.1134/S0026893310061032]
[29]
Zhu, Y.; Li, Y.; Zhu, S.; Tang, R.; Liu, Y.; Li, J. Association of survivin polymorphisms with tumor susceptibility: a meta-analysis. PLoS One, 2013, 8(9), e74778.
[http://dx.doi.org/10.1371/journal.pone.0074778] [PMID: 24098667]
[30]
Dai, J.; Jin, G.; Dong, J.; Chen, Y.; Xu, L.; Hu, Z.; Shen, H. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J. Thorac. Oncol., 2010, 5(11), 1748-1754.
[http://dx.doi.org/10.1097/JTO.0b013e3181f18cb9] [PMID: 20881643]
[31]
Yang, X.; Xiong, G.; Chen, X.; Xu, X.; Wang, K.; Fu, Y.; Yang, K.; Bai, Y. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol., 2009, 135(10), 1341-1349.
[http://dx.doi.org/10.1007/s00432-009-0575-7] [PMID: 19352701]
[32]
Jang, J.S.; Kim, K.M.; Kang, K.H.; Choi, J.E.; Lee, W.K.; Kim, C.H.; Kang, Y.M.; Kam, S.; Kim, I.S.; Jun, J.E.; Jung, T.H.; Park, J.Y. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer, 2008, 60(1), 31-39.
[http://dx.doi.org/10.1016/j.lungcan.2007.09.008] [PMID: 17961802]
[33]
Li, Y.; Wang, J.; Jiang, F.; Lin, W.; Meng, W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med. Genet., 2012, 13(1), 1.
[http://dx.doi.org/10.1186/1471-2350-13-1] [PMID: 22214342]
[34]
Abdelfattah, A.A.M.; Rizk, F.; Hawash, N.; Hanafy, A.; El-Kalla, F.; Abd-Elsalam, S. Randomized trial of preoperative administra-tion of oral pregabalin for postoperative analgesia in patients sche-duled for radiofrequency ablation of focal lesions in the liver. Int. J. Hyperthermia, 2018, 34(8), 1367-1371.
[35]
Negm, O.; Abou Saif, S.; El Gharib, M.; Yousef, M.; Abd-Elsalam, S. Role of low-molecular-weight heparins in prevention of throm-boembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 2017, 29(3), 317-321.